• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon

Innovative Approaches For Therapy Development Against Inflammatory Bowel Disease: An Expert Discussion

Unravelling IBD Therapeutics

Inflammatory bowel disease (IBD) is a complex condition with poorly understood mechanisms, and unknown causality. Despite its rapidly growing prevalence worldwide, IBD has a large, unmet therapeutic need, with a remarkably high failure rate of new drugs to enter the market. Increased understanding of the immunopathology of IBD has resulted in the development of novel therapies such as vedolizumab or ustekinumab, and the investigation of new agents including Janus kinase inhibitors, anti-mucosal vascular addressing cell adhesion molecule-1 agents, anti-interleukin-12/23 monoclonal antibody and sphingosine-1-phosphate receptor-1 selective agonists.

In this roundtable discussion, a panel of experts from pharma, biotech, and academia discuss challenges in the diagnosis and treatment of IBD, sharing their perspectives on current approaches towards the disease, and consider paradigm shifts happening within IBD drug development.

Key discussion points:

  • The definition of IBD: one, a few, or many diseases?
  • Current approaches against IBD, their successes and failures
  • What we can expect from human phenotypic models in IBD drug development
  • Taking steps towards personalized therapies, using biomarkers, genomics, transcriptomics, and phenomics
  • The most promising novel therapeutic approaches

Meet the panel

Gijs van den Brink, M.D., Ph.D
Roche, Senior Vice President, Global Head of Immunology, Infectious Disease and Ophthalmology

Prof. dr. Willem Bemelman

Amsterdam UMC, Professor Gastroenterology Endocrinology Metabolism, Professor, CCA - Cancer Treatment and Quality of Life, Professor, Surgery


Jos Joore, Ph.D
Co-CEO and co-founder of MIMETAS


Related publications

Watch the Roundtable Discussion by filling out the form below


May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all